"Novo is a pharmaceutical stock with a key focus on treating diabetes. As the incidence of diabetes has risen in the U.S. and elsewhere, Novo's insulin and blood-sugar drugs have become market leaders.
That doesn't mean Novo has had a free ride, though. Amylin, which Bristol-Myers Squibb (NYSE: BMY ) bought this summer, got FDA approval for Bydureon, a drug that requires only weekly injections rather than the daily injections that Novo's Victoza requires. Moreover, MannKind (Nasdaq: MNKD ) is still fighting for approval on its inhaled insulin product Afreeza. If approved, Afreeza could do away with injections entirely for many diabetics, a Holy Grail in diabetes research that eluded giants Pfizer (NYSE: PFE ) and Eli Lilly (NYSE: LLY ) as well as Novo.
Lately, Novo has suffered from the European financial crisis, as investors have steered away from European stocks regardless of their particular exposure to the Continent. Novo gets less than 30% of its revenue from Europe, though, with North America and other international operations drawing the lion's share of its sales.
For Novo to improve, it needs to keep working on ways to cement its place within the diabetes and insulin spaces. Whether that means buying out potential competitors like MannKind or coming up with new developments on its own remains to be seen, but if it can succeed in either of those directions, it could go a long way toward helping the company get closer to perfection in the years ahead."
Novo will be positioned to continue as a superpower in the diabetes space if it's able to buy or partner with MNKD for AFREZZA. If it doesn#$%$ future will be in jeopardy.
If MNKD doesn't do something fast, it looks like they will be out of money shortly. I've seen shareholders burned badly when the biotech they own has less than 1 year cash burn on hand. I don't know much about the company, so maybe they have something up their sleeve. Anyway, good luck to you.
MNKD is a losing proposition; NVO know it and so do ALL the other "big pharmas". The lungs are not designed for drug delivery. The long term effects on lung function cannot be known until the lawsuits for damages begin. Further, MANY who need insulin already have poorly functioning lungs. Perhaps the healthy could withstand a repeated insult to lung tissue but then the healthy don't need insulin. However, opinions are what make a market. Good luck with yours.
If the "lungs weren't designed for drug delivery" then why did Novo embark on a multi-billion dollar trek toward inhaled insulin of it's own not long ago? Your statement is non factual and down right silly. Inhaled meds that avoid needle injection and are ultra rapid acting are the future of medicine in many market segments. Inhaled meds are also the future of rebranding for many drugs that go off patent protection.